Skip to the reading
IpamorelinIn Frame

Find the Ipamorelin paper behind the claim

No need to read everything at once. Start with the source that matches the question you came with.

For the animal findings

Raun and colleagues, 1998, European Journal of Endocrinology. The early work on growth hormone release involved cells, rats and pigs. “Selective” refers to the hormone response, not proven safety in people.

Johansen and colleagues, 1999, Growth Hormone & IGF Research. Female rats had faster lengthwise bone growth. Total blood IGF-1, a protein involved in growth, stayed unchanged.

Svensson and colleagues, 2000, Journal of Endocrinology. Female rats had bigger bones containing more mineral, without higher mineral density by volume. That qualification belongs with the result.

Andersen and colleagues, 2001, Growth Hormone & IGF Research. Ipamorelin countered a drop in bone formation in rats receiving a steroid medicine. CJC-1295 wasn’t tested.

Those papers explain the interest in bones. They don’t establish a human bone treatment. For the human work, the questions change.

Read the bone explanation

For what happened in people

Gobburu and colleagues, 1999, Pharmaceutical Research. Healthy men received Ipamorelin into a vein. Researchers measured blood levels and growth hormone release, not a bone benefit.

Beck and colleagues, 2014, International Journal of Colorectal Disease. The bowel-surgery trial didn’t establish statistically clear benefit on its main or other effectiveness measures.

The second bowel-surgery trial, ClinicalTrials.gov. It finished in 2014. The registry record had no posted results as of October 1, 2026, leaving the outcome unknown.

Mayfield and colleagues, 2026, American Journal of Sports Medicine. A narrative review of injectable peptide research, not a human trial of CJC-1295 with Ipamorelin. The rat bone experiment above didn’t test that pairing, and neither source establishes a human height benefit.

The trial paper and FDA’s assessment are worth reading together. They give the safety discussion its hospital context.

Go to the human research

For safety and access questions

FDA’s 2024 Ipamorelin assessment covers the ingredients, human studies, observed hospital events and possible risks. It also describes important missing safety information. Possible risks aren’t the same as measured rates of harm.

FDA’s bulk-substance safety page, current as of April 22, 2026. Ipamorelin acetate appears in 503B Category 2 and among withdrawn 503A nominations. Withdrawal isn’t clearance; FDA gives no withdrawal date.

HHS guidance on care across state lines explains licensing routes. State rules determine what applies where the patient is during care.

These dates identify the records discussed here. A treatment conversation also needs the rules that apply at the time of care.

Return to the opening page